Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul;41(5):926-929.
doi: 10.1007/s10875-021-00996-7. Epub 2021 Feb 20.

Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia

Emily McKemey #  1 , Adrian M Shields #  2   3 , Sian E Faustini  4 , Harriet J Hill  5 , Aliaksandra Barnskaya  1 , Zania Stamataki  5 , Simon Gompertz  1 , Alex G Richter  1   4 , Davinder Dosanjh  1 , Shyam Madathil  1
Affiliations
Comment

Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia

Emily McKemey et al. J Clin Immunol. 2021 Jul.

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
a Serial serum IgG (gray), IgA (blue), and IgM (red) measurements over time. Normal ranges are shown by dotted lines. Asterisk “*” represents date rituximab was initiated. b Changes in peripheral blood neutrophil count, lymphocyte count, C-reactive protein, and temperature over the time course of disease relative to pharmacological treatments received. Time course is relative to the first presentation on 16/4/2020. c Level of serum IgG, IgA, and IgM anti-SARS-CoV-2 trimeric spike glycoprotein antibodies were measured before and after treatment with convalescent plasma. Results are expressed as a signal to the cutoff calibrator ratio with the dotted line representing the cutoff for positivity. d In vitro SARS-CoV-2 neutralizing activity of serum from the patient before (day 91) and after (day 106 and day 119) the administration of convalescent plasma. Dex, dexamethasone; PCR, polymerase chain reaction; CT, cycle threshold; TMA, transcription-mediated amplification
See this image and copyright information in PMC

Comment on

References

    1. London J, et al. Severe COVID-19 in patients with B cell alymphocytosis and response to convalescent plasma therapy. J Clin Immunol. 2021;41(2):356–61. - PMC - PubMed
    1. Shields AM et al. COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. J Allergy Clin Immunol. 2020;S0091–6749(20)32406-4. - PMC - PubMed
    1. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, ACTT-1 Study Group Members Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813–1826. doi: 10.1056/NEJMoa2007764. - DOI - PMC - PubMed
    1. RECOVERY Collaborative Group et al. Dexamethasone in hospitalized patients with covid-19 - Preliminary report. N Engl J Med. 2020. - PMC - PubMed
    1. Simonovich VA et al. A randomized trial of convalescent plasma in covid-19 severe pneumonia. N Engl J Med 2021;384:619–29. - PMC - PubMed

LinkOut - more resources